JPRN-jRCT2071200055尚未招募1 期
Safety, tolerability and pharmacokinetics of single and multiple rising doses of BI 764198 in Japanese healthy male subjects (double-blind, randomised, placebo-controlled within dose groups, parallel group design)
Ogawa Shintaro0 个研究点目标入组 44 人开始时间: 2020年11月25日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 45age old（—）
- 性别
- Male
入选标准
- •Healthy male subjects, age of 20 to 45 years (inclusive), body mass index (BMI) of 18.5 to 25.0 kg/m2 (inclusive)
排除标准
- •1.Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator
- •2.Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 bpm
- •3.Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
- •4.Any evidence of a concomitant disease assessed as clinically relevant by the investigator
研究者
相似试验
暂停
1 期
A study in healthy Japanese men to test how different doses of BI 894416 are toleratedJPRN-jRCT2080225328ippon Boehringer Ingelheim Co., Ltd.24
招募中
1 期
A study in healthy Japanese men to test how well different dosesof BI 1569912 are toleratedMajor Dipressive DisorderJPRN-jRCT2071210037Furuichi Takumi44
已完成
1 期
A study in healthy Japanese men to test how different doses of BI 1323495 are tolerated and how itraconazole influences the amount of BI 1323495 in the bloodJPRN-jRCT2071200056Katakabe Tetsuya74
进行中（未招募）
不适用
The purpose of this study is to describe the pharmacokinetics of moxifloxacin in children to see what the best dose should be for children in the future. Pharmacokinetics is to see how the body absorbs, distributes, breaks down and gets rid of the study drug.o medical condition specified as the purpose of this study is to describe the pharmacokinetics of moxifloxacin in children for future antibiotic treatment.EUCTR2012-000737-40-Outside-EU/EEABayer HealthCare Pharmaceuticals36
进行中（未招募）
1 期
A study to test different doses of BI 836880 in patients with an eye disease called wet age-related macular degeneration (wAMD)wet age-related macular degeneration (wAMD)MedDRA version: 20.1Level: PTClassification code 10064930Term: Age-related macular degenerationSystem Organ Class: 10015919 - Eye disordersMedDRA version: 20.0Level: LLTClassification code 10075568Term: Wet age-related macular degenerationSystem Organ Class: 10015919 - Eye disordersMedDRA version: 20.0Level: LLTClassification code 10075718Term: Exudative age-related macular degenerationSystem Organ Class: 10015919 - Eye disordersEUCTR2017-001221-40-DEBoehringer Ingelheim Pharma GmbH & Co. KG42